What is the side‑effect profile of selpercatinib (Retevmo)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Selpercatinib Side Effect Profile

Selpercatinib demonstrates a markedly favorable tolerability profile compared to multikinase inhibitors, with only 2-5% of patients requiring permanent discontinuation due to adverse events, and most side effects manageable through dose modifications rather than treatment cessation.

Most Common Adverse Events (≥25% of patients)

Based on the LIBRETTO-001 trial safety data from 702 patients across all RET-altered solid tumors 1:

Laboratory abnormalities:

  • Increased AST or ALT (most common)
  • Increased glucose
  • Decreased leukocytes
  • Decreased albumin
  • Decreased calcium
  • Decreased sodium
  • Decreased platelets
  • Increased creatinine
  • Increased alkaline phosphatase
  • Increased total cholesterol

Clinical adverse events:

  • Dry mouth
  • Diarrhea
  • Hypertension
  • Fatigue
  • Edema (peripheral swelling)
  • Rash
  • Constipation

Grade 3-4 Adverse Events

The most common severe adverse events 1, 2:

  • Hypertension (18-20%) - most frequent severe toxicity
  • Increased ALT (9-12%)
  • Increased AST (8-10%)
  • Hyponatremia (9.2%)

In the LIBRETTO-431 trial comparing selpercatinib to chemotherapy, Grade 3-4 adverse events occurred in 70.3% of selpercatinib patients versus 57.1% with chemotherapy 2. However, the critical distinction is that dose reductions (51.3% vs 28.6%) and permanent discontinuations (10.1% vs 2%) were more common with selpercatinib, yet only 4.8% discontinued selpercatinib versus 27% in the control arm 3.

Serious Adverse Events Requiring Monitoring

Hepatotoxicity

  • Elevated transaminases are the most common reason for dose interruption (42% of patients) 1
  • Typically reversible with dose modification
  • Rare cases of severe drug-induced liver injury have been documented 4
  • Monitor liver function tests regularly throughout treatment

Cardiovascular Effects

  • Hypertension is the most common Grade 3+ adverse event 3, 1
  • QT prolongation (20% any grade, 9% Grade 3+) 5
  • Rare myocardial infarction (1.3%) 5
  • Monitor blood pressure and ECG with electrolytes before and during treatment 5

Hemorrhagic Events

  • Bleeding complications can occur and may be serious 5
  • Monitor for signs of bleeding throughout treatment

Other Clinically Significant Events

  • Hypothyroidism (9%) - requires thyroid function monitoring 5
  • Tumor lysis syndrome - maintain adequate hydration 5
  • Wound healing complications - discontinue 7 days before planned surgery 5
  • Allergic reactions (fever, rash, joint pain) - especially during first month 5
  • Hip joint problems (slipped capital femoral epiphysis) in pediatric patients 5

Dose Modifications

Critical management principle: Adverse events are highly manageable through dose adjustments rather than discontinuation 3:

  • Dose reductions required: 30-51% of patients 3, 5
  • Dose interruptions required: 42-49% of patients 1, 5
  • Permanent discontinuation: Only 2-4.8% of patients 3, 1

This contrasts sharply with multikinase inhibitors where discontinuation rates reach 12-27% 3.

Comparative Tolerability

Selpercatinib demonstrates superior tolerability versus multikinase inhibitors 3:

Vandetanib:

  • Grade 3-4 adverse events: 50%
  • Dose reduction: 33%
  • Discontinuation: 12%

Cabozantinib:

  • Grade 3-4 adverse events: 75%
  • Dose reduction: 80%
  • Discontinuation: 20%

Selpercatinib:

  • Grade 3-4 adverse events: 39-70%
  • Dose reduction: 30-51%
  • Discontinuation: 2-4.8%

Long-Term Safety Profile

With median follow-up of 45.4 months in 837 patients 6:

  • The adverse event profile remains consistent over time
  • Most common events at <6 months: fatigue (36.6%), dry mouth (32.8%), ALT increased (30.5%)
  • Most common events at ≥24 months: edema (63.2%), diarrhea (60.7%), fatigue (53.0%)
  • Long-term treatment is feasible with appropriate dose management

Pediatric Considerations

In children ≥2 years 5:

  • Most common: muscle/bone pain, diarrhea, headache, nausea, vomiting
  • Unique risk: slipped capital femoral epiphysis - monitor for hip/knee pain or painless limp
  • Most common severe lab abnormalities: decreased calcium, decreased RBC count, decreased WBC count

Key Clinical Pitfalls to Avoid

  1. Do not discontinue prematurely for transaminase elevation - dose interruption and reduction typically resolve this without permanent cessation 1

  2. Monitor creatinine carefully - selpercatinib causes 18% increase in serum creatinine through inhibition of renal transporters, not true renal dysfunction; consider alternative renal function markers 5

  3. Proactive blood pressure management - hypertension is predictable and manageable with standard antihypertensives 5

  4. Perioperative planning - discontinue 7 days before surgery to prevent wound healing complications 5

References

Related Questions

What lab tests and monitoring schedule should be performed for an adult patient receiving selpercatinib (Retevmo) for RET‑fusion positive lung cancer or medullary thyroid carcinoma?
In a 45-year-old male construction worker with a history of asthma who presents with three days of left-sided chest discomfort, one day of fever (38 °C) that resolved with acetaminophen, sore throat, dysphonia, nasal congestion, rhinorrhea, and a frontal pressure headache (EVA 6/10), without cough, wheezing, cyanosis, or other red-flag symptoms, what is the most likely diagnosis and what initial management should be recommended?
What is the appropriate cefuroxime dosage per kilogram of body weight?
What is the appropriate stat intravenous digoxin dose for an adult?
What is the next treatment for a patient whose knee MRI shows an age‑indeterminate small horizontal oblique tear of the posterior horn of the medial meniscus and grade 4 chondromalacia of the central femoral trochlear groove?
Do hyaline casts in a urinalysis always indicate nephrolithiasis?
Can the combination of carboplatin, pemetrexed, and pembrolizumab cause acute kidney injury?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.